Literature DB >> 9658130

Overexpression of an alternatively spliced form of c-Myb results in increases in transactivation and transforms avian myelomonoblasts.

C H Woo1, L Sopchak, J S Lipsick.   

Abstract

An alternatively spliced form of c-myb exists that encodes an additional 120 amino acids in chicken and 121 amino acids in human and mouse. These amino acids are encoded by an additional exon, termed exon 9A. This exon is not present in v-myb, and proteins containing these amino acids have never been tested for oncogenic transformation. A series of myb constructs was therefore created in order to compare the functions of Myb proteins on the basis of their inclusion or exclusion of the amino acids encoded by exon 9A (E9A). We found that the presence of E9A resulted in a robust increase in transactivation for full-length c-Myb (CCC), as well as the singly truncated derivatives dCC and CCd, while doubly truncated Myb proteins v-Myb (dVd) and dCd did not exhibit any differences in transactivation. The increase in transactivation requires the Myb DNA-binding domain. When the leukemic transformation by the Myb proteins was tested, it was found that cells transformed by dVd resembled monoblasts, while cells transformed by CCC and its derivatives, dCd, dCC, and CCd, resembled myelomonoblasts. Despite differences in the morphology of the hematopoietic cells, the cell surface phenotypes and cell cycle profiles of transformed cells did not change for each pair of Myb proteins in the presence or absence of E9A. Thus, there was no direct correlation between the level of transcriptional activation and the strength of leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658130      PMCID: PMC109890     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Mutations in the DNA-binding and transcriptional activation domains of v-Myb cooperate in transformation.

Authors:  P W Dini; J T Eltman; J S Lipsick
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

2.  Solution structure of a specific DNA complex of the Myb DNA-binding domain with cooperative recognition helices.

Authors:  K Ogata; S Morikawa; H Nakamura; A Sekikawa; T Inoue; H Kanai; A Sarai; S Ishii; Y Nishimura
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

3.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

4.  c-Myb prevents TPA-induced differentiation and cell death in v-Myb transformed monoblasts.

Authors:  J Smarda; J S Lipsick
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

5.  Distribution of alternatively spliced chicken c-myb exon 9A among hematopoietic tissues.

Authors:  E R Schuur; J M Rabinovich; M A Baluda
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

6.  Dominant interfering alleles define a role for c-Myb in T-cell development.

Authors:  P Badiani; P Corbella; D Kioussis; J Marvel; K Weston
Journal:  Genes Dev       Date:  1994-04-01       Impact factor: 11.361

7.  Only late, nonmitotic stages of granulocyte differentiation in 32Dcl3 cells are blocked by ectopic expression of murine c-myb and its truncated forms.

Authors:  J Bies; R Mukhopadhyaya; J Pierce; L Wolff
Journal:  Cell Growth Differ       Date:  1995-01

8.  Identification of alternatively spliced transcripts for human c-myb: molecular cloning and sequence analysis of human c-myb exon 9A sequences.

Authors:  P Dasgupta; E P Reddy
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

9.  A central role for a single c-Myb binding site in a thymic locus control region.

Authors:  K C Ess; T L Whitaker; G J Cost; D P Witte; J J Hutton; B J Aronow
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

10.  Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb.

Authors:  P Melotti; D H Ku; B Calabretta
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  8 in total

1.  Evolutionary conservation of alternative splicing in chicken.

Authors:  S Katyal; Z Gao; R-Z Liu; R Godbout
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

2.  Functional analysis of carboxy-terminal deletion mutants of c-Myb.

Authors:  D M Wang; J W Dubendorff; C H Woo; J S Lipsick
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  p89c-Myb is not required for fetal or adult hematopoiesis.

Authors:  Stacey J Baker; Atul Kumar; E Premkumar Reddy
Journal:  Genesis       Date:  2010-05       Impact factor: 2.487

4.  Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb.

Authors:  Atul Kumar; Stacey J Baker; Clement M Lee; E Premkumar Reddy
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

5.  Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.

Authors:  John P O'Rourke; Scott A Ness
Journal:  Mol Cell Biol       Date:  2008-01-14       Impact factor: 4.272

Review 6.  Myb proteins: angels and demons in normal and transformed cells.

Authors:  Ye Zhou; Scott A Ness
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

7.  Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL.

Authors:  Ye E Zhou; John P O'Rourke; Jeremy S Edwards; Scott A Ness
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

8.  Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells.

Authors:  G Manzotti; S A Mariani; F Corradini; R Bussolari; V Cesi; J Vergalli; G Ferrari-Amorotti; V Fragliasso; A R Soliera; S Cattelani; G Raschellà; T L Holyoake; B Calabretta
Journal:  Blood Cancer J       Date:  2012-05-11       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.